Author Question: Refer to Exhibit 11-1. Failure to control history and maturation is a definite weakness. a. ... (Read 82 times)

casperchen82

  • Hero Member
  • *****
  • Posts: 540
Refer to Exhibit 11-1. Failure to control history and maturation is a definite weakness.
 
  a. One-group, pretest-posttest design
  b. Randomized subjects, posttest only, control-group design
  c. Randomized subjects, pretest-posttest design control-group
  d. Randomized Solomon four-group design
  e. Counterbalanced design

Question 2

Refer to Exhibit 11-1. Includes more than one control group with one group receiving neither pretest nor treatment.
 
  a. One-group, pretest-posttest design
  b. Randomized subjects, posttest only, control-group design
  c. Randomized subjects, pretest-posttest, control-group design
  d. Randomized Solomon four-group design
  e. Counterbalanced design



ansleighelindsey

  • Sr. Member
  • ****
  • Posts: 364
Answer to Question 1

A

Answer to Question 2

D



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

Congestive heart failure is a serious disorder that carries a reduced life expectancy. Heart failure is usually a chronic illness, and it may worsen with infection or other physical stressors.

Did you know?

If you use artificial sweeteners, such as cyclamates, your eyes may be more sensitive to light. Other factors that will make your eyes more sensitive to light include use of antibiotics, oral contraceptives, hypertension medications, diuretics, and antidiabetic medications.

Did you know?

The FDA recognizes 118 routes of administration.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library